Clinical trial · Observational
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma
The Impact of the Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B Cell Lymphoma
NCT02060435CI-TRIAL-00013737completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators analyzed clinical outcome in DLBCL patients according to age group to define the impact of EBV status on the clinical outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EBER | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- EBER+ AMC
- description
- EBV+DLBCL patients in Asan Medical Center
- interventionNames
- Other: EBER
- label
- EBER+ SMC
- description
- EBV+DLBCL patients in Samsung Medical Center
- interventionNames
- Other: EBER
- label
- EBER- SMC
- description
- EBV-DLBCL patients in Samsung Medical Center
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- Two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed de novo DLBCL, according to the World Health Organization (WHO) classification: * registered in Samsung Medical Center (SMC) Lymphoma Cohort Study I/II (ClinicalTrials.gov Identifier: NCT00822731, NCT01877109) or identified from Asan Medical Center (AMC) medical database: * adequate amount and quality of paraffin-embedded biopsy specimen or unstained slides for EBV-encoded RNA (EBER) in situ hybridization. Exclusion Criteria: * Patients with unknown EBV status, primary central nervous system (CNS) lymphoma, post-transplant lymphoproliferative disorders (PTLDs), and HIV-positive DLBCL were excluded in the study.
References
Publications (1)
- DERIVEDHong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4. PMID 25475080